Processing

Please wait...

Settings

Settings

1. WO2020006119 - METHODS FOR TREATING AGITATION USING DEXMEDETOMIDINE HYDROCHLORIDE

Publication Number WO/2020/006119
Publication Date 02.01.2020
International Application No. PCT/US2019/039308
International Filing Date 26.06.2019
IPC
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
4164
1,3-Diazoles
4174
Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
A61K 31/4174 (2006.01)
A61P 25/00 (2006.01)
CPC
A61K 31/4174
A61P 25/00
Applicants
  • BIOXCEL THERAPEUTICS, INC. [US/US]; 555 Long Wharf Drive New Haven, Connecticut 06511, US
Inventors
  • YOCCA, Frank; US
  • DEVIVO, Michael; US
Agents
  • BROWN, Fraser D.; US
  • CAFFIN, Lee; US
  • TUSCAN, Michael S.; US
Priority Data
62/690,40727.06.2018US
62/767,42214.11.2018US
62/787,64902.01.2019US
62/798,84230.01.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHODS FOR TREATING AGITATION USING DEXMEDETOMIDINE HYDROCHLORIDE
(FR) MÉTHODES DE TRAITEMENT DE L'AGITATION FAISANT APPEL À DU CHLORHYDRATE DE DEXMÉDÉTOMIDINE
Abstract
(EN)
The present disclosure relates to the treatment of agitation or signs of agitation in certain human subjects, including subjects with a neurodegenerative, neuropsychiatric or opioid withdrawal disorder, by administering dexmedetomidine hydrochloride by the intravenous route.
(FR)
La présente invention concerne le traitement de l'agitation ou des signes d'agitation chez certains sujets humains, y compris des sujets atteints d'un trouble neurodégénératif, neuropsychiatrique ou de sevrage d'un opioïde, par l'administration de chlorhydrate de dexmédétomidine par voie intraveineuse.
Latest bibliographic data on file with the International Bureau